Vallon Pharmaceuticals (VLON) Short Interest Ratio & Short Volume

Short interest is the volume of Vallon Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of March 31st, traders have sold 90,700 shares of VLON short. 0.98% of Vallon Pharmaceuticals' shares are currently sold short. Learn More on Vallon Pharmaceuticals' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.98% of Vallon Pharmaceuticals' floating shares are currently sold short.

Vallon Pharmaceuticals saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 90,700 shares, a drop of 59.6% from the previous total of 224,600 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Vallon Pharmaceuticals currently has issued a total of 13,482,000 shares. Some of Vallon Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Vallon Pharmaceuticals currently has a public float of 9,250,000 shares.

0.98% of Vallon Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Vallon Pharmaceuticals: Tenax Therapeutics, Inc. (2.62%), Trevena, Inc. (0.63%), Chemomab Therapeutics Ltd. (1.87%), eFFECTOR Therapeutics, Inc. (10.72%), Sunshine Biopharma, Inc. (0.77%), Enveric Biosciences, Inc. (4.23%), Shuttle Pharmaceuticals Holdings, Inc. (0.72%), Pasithea Therapeutics Corp. (1.17%), Pulmatrix, Inc. (0.07%), Ainos, Inc. (4.81%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($4.66 billion), TC Energy Co. ($4.13 billion), Occidental Petroleum Co. ($3.04 billion), Moderna, Inc. ($2.63 billion), Coinbase Global, Inc. ($2.51 billion), T. Rowe Price Group, Inc. ($2.29 billion), Paramount Global ($2.26 billion), Verisk Analytics, Inc. ($2.19 billion), Etsy, Inc. ($1.84 billion), and Voya Financial, Inc. ($1.67 billion). View all of the most shorted stocks.

Short selling VLON is an investing strategy that aims to generate trading profit from Vallon Pharmaceuticals as its price is falling. VLON shares are trading up $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Vallon Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of VLON, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including VLON, twice per month. The most recent reporting period available is March, 31 2023.